← Back to headlines
Neurocrine Acquires Soleno, Gains Drug for Prader-Willi Syndrome
Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics, thereby securing a promising drug designed to treat a rare genetic disorder characterized by relentless hunger.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
